Dashboard
Manage Tickers

ARVN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

goldman-sachs-downgrades-arvinas-to-sell-lowers-price-target-to-6
Goldman Sachs Downgrades Arvinas to Sell, ...
10/15/2025 11:24:51

Goldman Sachs analyst Paul Choi downgrades Arvinas (NASDAQ:ARVN) from Neutral to Sell and lowers the price target from $8 to...

Core News & Articles
Arvinas And Pfizer To Highlight New Vepdeg...
10/13/2025 11:08:29

Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial 

reported-sunday-arvinas-unveils-late-breaking-phase-1-data-for-arv-102-showing-90-lrrk2-reduction-and-modulation-of-neuroinflammatory-pathways
Reported Sunday, Arvinas Unveils Late-Brea...
10/06/2025 06:29:32

arvinas-to-present-arv-102-data-at-2025-international-congress-of-parkinsons-disease-and-movement-disorders-oct-7-and-8
Arvinas To Present ARV-102 Data At 2025 In...
10/01/2025 11:03:59

btig-maintains-buy-on-arvinas-lowers-price-target-to-10
BTIG Maintains Buy on Arvinas, Lowers Pric...
09/18/2025 14:08:11

BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $16 to $10.

stephens--co-maintains-overweight-on-arvinas-lowers-price-target-to-14
Stephens & Co. Maintains Overweight on Arv...
09/18/2025 12:03:47

Stephens & Co. analyst Sudan Loganathan maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target fr...

arvinas-to-reduce-workforce-by-15-most-significant-reductions-being-roles-related-to-vepdegestrant-commercialization-expects-45m-costs-for-workforce-reduction
Arvinas To Reduce Workforce By 15%; Most S...
09/17/2025 20:53:03

arvinas-says-additional-cost-optimization-measures-expected-to-realize-total-annual-savings-of-more-than-100m-compared-to-fy24-board-authorizes-100m-stock-repurchase
Arvinas Says Additional Cost Optimization ...
09/17/2025 20:33:10

Core News & Articles
Arvinas Provides Update On Pfizer Collabor...
09/17/2025 20:32:31

what-4-analyst-ratings-have-to-say-about-arvinas
What 4 Analyst Ratings Have To Say About A...
09/17/2025 12:00:52

Core News & Articles
Arvinas And Pfizer Announce FDA Accepts Ne...
08/08/2025 20:06:48

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful im...

hc-wainwright--co-maintains-buy-on-arvinas-lowers-price-target-to-18
HC Wainwright & Co. Maintains Buy on Arvin...
08/07/2025 15:49:27

HC Wainwright & Co. analyst Andrew S. Fein maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $...

wells-fargo-maintains-overweight-on-arvinas-lowers-price-target-to-16
Wells Fargo Maintains Overweight on Arvina...
08/07/2025 14:30:56

Wells Fargo analyst Derek Archila maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $19 to ...

guggenheim-maintains-buy-on-arvinas-lowers-price-target-to-15
Guggenheim Maintains Buy on Arvinas, Lower...
08/07/2025 14:14:07

Guggenheim analyst Michael Schmidt maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $16 to $15.

arvinas-says-cash-cash-equivalents-and-marketable-securities-of-8612m-as-of-june-30-2025-is-sufficient-to-fund-planned-operating-expenses-and-capital-expenditure-requirements-into-2h-of-2028
Arvinas Says Cash, Cash Equivalents, And M...
08/06/2025 11:09:13

arvinas-q2-eps-084-beats-103-estimate-sales-22400m-miss-30374m-estimate
Arvinas Q2 EPS $(0.84) Beats $(1.03) Estim...
08/06/2025 11:06:32

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

arvinas-begins-ceo-search-as-longtime-leader-john-houston-plans-exit-from-top-role-will-stay-on-as-board-chair
Arvinas Begins CEO Search as Longtime Lead...
07/09/2025 11:05:27

Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted p...

wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-corrected
Wall Street's Most Accurate Analysts Give ...
06/18/2025 15:15:09

arvinas-presents-data-from-preclinical-studies-of-arv-393-protac-b-cell-lymphoma-6-protein-degrader-at-eha-2025-congress
Arvinas Presents Data From Preclinical Stu...
06/13/2025 11:04:15

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblast...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION